Form 4 for HRTX HERON THERAPEUTICS, INC. /DE/
Accepted 2022-12-20 00:00:00 ET · period of report 2022-12-16 · accession 0001209191-22-062187 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-20 | 2022-12-16 | HRTX | Dissanaike Sharmila | Dir | A - Grant | $0.00 | +38.6K | 55.3K | +231% | $0 |
| D | 2022-12-20 | 2022-12-16 | HRTX | Dissanaike Sharmila | Dir | A - Grant | $0.00 | +77.2K | 77.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-16 | A | A | 38,580 | $0.00 | 55,282 | D | — | — | (F1) The shares were granted as restricted stock units which vest in full on December 16, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-12-16 | A | A | 77,160 | $0.00 | 77,160 | D | $2.74 · — to 2032-12-16 | 77,160 Common Stock | (F2) The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. |